- Home
- MTAK vs WHWK Comparison
MTAK vs WHWK Comparison
Compare MTAK & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$3.52
Company Overview
Basic Information| Metric | MTAK | WHWK |
|---|---|---|
| Founded | 2026 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.2M | 213.2M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MTAK | WHWK |
|---|---|---|
| Price | $9.84 | $3.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.71 |
| AVG Volume (30 Days) | 43.7K | ★ 311.4K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.83 | $1.87 |
| 52 Week High | $9.93 | $5.50 |
Technical Indicators
Market Signals| Indicator | MTAK | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 25.00 | 31.56 |
| Support Level | N/A | $3.36 |
| Resistance Level | N/A | $3.88 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 24.69 | 22.02 |
Price Performance
Historical Comparison MTAK
WHWK
About MTAK Market Technology Acquisition Corp Class A Ordinary Shares
Market Technology Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.